Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 308

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 308
---
|:--|:----|:--------|-------:|:----|:------|-------:|
|                   |     | Level 1        |   |     | Level 2 |   |     | Level 3 |        |     | Total |        |
| Earnout liability |     | $              | - |     | $       | - |     | $       | 20,000 |     | $     | 20,000 |

|                   |     | December 31, 2024 |   |     |         |   |     |         |        |     |       |        |
|:------------------|:----|:------------------|:--|:----|:--------|:--|:----|:--------|-------:|:----|:------|-------:|
|                   |     | Level 1           |   |     | Level 2 |   |     | Level 3 |        |     | Total |        |
| Earnout liability |     | $                 | - |     | $       | - |     | $       | 20,000 |     | $     | 20,000 |

The change in the fair value measurement using
significant inputs (Level 3) is summarized below:

| Preferred stock warrant liability (Predecessor): |     |   |            |   |
|:-------------------------------------------------|:----|:--|-----------:|:--|
| Balance at December 31, 2023                     |     | $ |    320,117 |   |
| Gain on revaluation of warrant liability         |     |   |   (320,117 | ) |
| Balance at February 14, 2024                     |     | $ |          - |   |
| Earnout liability (Successor):                   |     |   |            |   |
| Balance at February 14, 2024                     |     | $ |  4,900,000 |   |
| Gain on revaluation of earnout liability         |     |   | (1,800,000 | ) |
| Balance at March 31, 2024                        |     | $ |  3,100,000 |   |

| Earnout liability (Successor):           |     |   |        |
|:-----------------------------------------|:----|:--|-------:|
| Balance at December 31, 2024             |     | $ | 20,000 |
|